#USA #Pittsburgh #Wound Care #MolecuLight #CAMPs Success

New Research on MolecuLight's Predictive Capabilities in Wound Care

MolecuLight, an innovator in point-of-care fluorescence imaging for wound care, has recently published two significant studies showcasing its ability to accurately predict the success of wound treatments known as CAMPs (Cellular and Molecular Proliferation). This groundbreaking research underscores the importance of assessing bacterial burden in wound beds, enhancing clinical decisions for better patient outcomes.

The first study, titled "Bacterial Fluorescence Signals Predict Dermal Regeneration Template Integration Outcomes," was spearheaded by Dr. Carlos Daniel Torres Garcia and Dr. Erik Hanson and published in the prestigious Wound Repair and Regeneration Journal. It focused on acute trauma wounds that required dermal regeneration templates (DRTs). The findings revealed a remarkable connection between bacterial fluorescence and DRT success rates. Specifically, areas without bacterial fluorescence boasted an impressive 85.6% success rate, whereas those with bacterial fluorescence showed a mere 14.4% success rate.

Similarly, the second study led by vascular surgeon Dr. Alisha R. Oropallo, MD, and featured in the Diagnostics Journal, provided new insights into diabetic foot ulcers (DFUs) and venous leg ulcers (VLUs). Despite clinical preparations for CAMP application, wounds exhibiting bacterial fluorescence before treatment showed an average increase in wound size over four weeks, highlighting the critical influence of bacterial presence on healing. Conversely, wounds without bacterial fluorescence indicated an early positive response, demonstrating over a 40% decrease in wound area within the same timeframe.

Dr. Oropallo emphasized, "Timing is crucial for achieving better outcomes with skin substitutes. Ensuring a clean wound bed is essential to minimizing infection chances, thus allowing the product's timely placement. By prioritizing wound hygiene, guided by MolecuLight, we can significantly enhance the likelihood of successful treatments. This study serves as compelling evidence supporting MolecuLight's utility prior to CAMP placement."

The significance of these findings has not gone unnoticed. Anil Amlani, CEO of MolecuLight, stated, "Two independent studies yielding similar outcomes highlight the importance of MolecuLight in helping clinicians evaluate wound readiness prior to CAMPs placement. Clinicians must ensure thorough documentation and optimal wound preparation to elevate patient outcomes. MolecuLight uniquely confirms elevated bacterial loads that could lead to CAMP failure. We commend both research teams for their exceptional work, and it is gratifying to see MolecuLight integrated into clinical practice."

Combining these two studies enhances the clinical evidence regarding the efficacy of MolecuLight's fluorescence imaging as a definitive tool for assessing bacterial burden during wound bed preparation. This technology allows healthcare professionals to visualize increased bacterial fluorescence on-site, empowering them to make informed decisions about when to initiate advanced therapies like CAMPs. By incorporating MolecuLight in the treatment process, clinicians are better equipped to navigate challenges encountered in wound management.

About MolecuLight

MolecuLight is a leading medical imaging company selected for its pioneering work in wound care. It manufactures and commercializes advanced wound imaging devices, including the MolecuLight iX® and DX®. These Class II FDA-cleared imaging systems enable healthcare providers to detect elevated bacterial levels in real-time and measure wounds accurately for effective management. Supported by over 100 peer-reviewed publications, MolecuLight continually aims to set new standards in wound care technology, promoting better patient outcomes.

Moreover, with the recent introduction of the Thermal Imaging Module, the MolecuLight DX now allows clinicians to visualize clinically relevant temperature changes right at the point of care, thereby further enhancing the wound assessment process.